$SLRN
ACELYRIN, Inc. Stock $slrn

$slrn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000196291824000052 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.64M	$24.74M	$11.91M
YoY Change	31.4%	107.69%
% of Gross Profit
Research & Development	$76.38M	$58.03M	$167.9M
YoY Change	154.35%	-65.44%	1191.39%
% of Gross Profit
Depreciation & Amortization	$116.0K	$55.00K	$0.00
YoY Change	329.63%
% of Gross Profit
Operating Expenses	$93.03M	$82.77M	$179.8M
YoY Change	117.88%	-53.97%	1018.02%
Operating Profit	-$93.03M	-$82.77M	-$179.8M
YoY Change	117.88%	-53.97%	1018.02%
Interest Expense	$8.447M	$9.150M	$3.446M
YoY Change	-49.81%	165.53%
% of Operating Profit
Other Income/Expense, Net	-$1.094M	$38.65M	-$63.00K
YoY Change	536.05%	-61450.79%
Pretax Income	-$85.67M	-$34.97M	-$176.5M
YoY Change	229.01%	-80.18%
Income Tax
% Of Pretax Income
Net Earnings	-$85.67M	-$34.97M	-$176.5M
YoY Change	229.01%	-80.18%	996.98%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.86	-$0.36	-$8.61
Diluted Earnings Per Share	-$0.86	-$0.36	-$8.61
COMMON SHARES
Basic Shares Outstanding	99.03M shares	98.37M shares	20.49M shares
Diluted Shares Outstanding	99.16M shares	97.91M shares	20.49M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$635.2M	$678.5M	$289.2M
YoY Change	-22.81%	134.63%
Cash & Equivalents	$128.2M	$264.5M	$289.2M
Short-Term Investments	$507.0M	$414.0M	$0.00
Other Short-Term Assets	$7.500M	$10.09M	$2.412M
YoY Change	11.56%	318.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$648.3M	$694.0M	$291.9M
YoY Change	-21.88%	137.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.509M	$2.179M	$238.0K
YoY Change	-23.48%	815.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$868.0K	$175.0K	$5.093M
YoY Change	-58.21%	-96.56%
Total Long-Term Assets	$3.478M	$3.503M	$6.663M
YoY Change	-34.8%	-47.43%
TOTAL ASSETS
Total Short-Term Assets	$648.3M	$694.0M	$291.9M
Total Long-Term Assets	$3.478M	$3.503M	$6.663M
Total Assets	$651.7M	$697.5M	$298.5M
YoY Change	-21.96%	133.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.72M	$9.994M	$10.77M
YoY Change	346.17%	-7.21%
Accrued Expenses	$40.60M	$41.71M	$19.61M
YoY Change	90.3%	112.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$82.45M	$52.28M	$33.66M
YoY Change	151.75%	55.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.069M	$1.134M	$11.61M
YoY Change	-18.33%	-90.24%
Total Long-Term Liabilities	$1.069M	$1.134M	$11.61M
YoY Change	-18.33%	-90.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$82.45M	$52.28M	$33.66M
Total Long-Term Liabilities	$1.069M	$1.134M	$11.61M
Total Liabilities	$83.52M	$53.42M	$45.28M
YoY Change	145.22%	17.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$609.4M	-$523.7M	-$283.5M
YoY Change	96.83%	84.73%
Common Stock	$1.000K	$1.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$568.2M	$644.1M	-$143.4M
YoY Change
Total Liabilities & Shareholders Equity	$651.7M	$697.5M	$298.5M
YoY Change	-21.96%	133.65%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$85.67M	-$34.97M	-$176.5M
YoY Change	229.01%	-80.18%	996.98%
Depreciation, Depletion And Amortization	$116.0K	$55.00K	$0.00
YoY Change	329.63%
Cash From Operating Activities	-$46.28M	-$57.30M	-$25.30M
YoY Change	46.35%	126.48%	73.29%
INVESTING ACTIVITIES
Capital Expenditures	$814.0K	$55.00K	$238.0K
YoY Change	-53.78%	-76.89%
Acquisitions
YoY Change
Other Investing Activities	-$88.37M	$101.0M	$150.4M
YoY Change	-66.79%	-32.87%
Cash From Investing Activities	-$89.18M	$100.9M	$47.54M
YoY Change	-66.71%	112.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-289.0K	$2.807M	-$129.0K
YoY Change	-100.05%	-2275.97%	-100.1%
NET CHANGE
Cash From Operating Activities	-46.28M	-$57.30M	-$25.30M
Cash From Investing Activities	-89.18M	$100.9M	$47.54M
Cash From Financing Activities	-289.0K	$2.807M	-$129.0K
Net Change In Cash	-135.7M	$46.40M	$22.08M
YoY Change	-150.85%	110.12%	-80.0%
FREE CASH FLOW
Cash From Operating Activities	-$46.28M	-$57.30M	-$25.30M
Capital Expenditures	$814.0K	$55.00K	$238.0K
Free Cash Flow	-$47.09M	-$57.36M	-$25.54M
YoY Change	41.07%	124.59%	74.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9994000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	41920000	usd
CY2024Q1	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	37529000	usd
CY2023Q4	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	35436000	usd
CY2024Q1	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	4182000	usd
CY2023Q4	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	6833000	usd
CY2024Q1	slrn	Severance Liability Current SeveranceLiabilityCurrent	578000	usd
CY2023Q4	slrn	Severance Liability Current SeveranceLiabilityCurrent	970000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	52283000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85159000	usd
CY2024Q1	us-gaap	Assets Assets	697484000	usd
CY2023Q4	us-gaap	Assets Assets	742690000	usd
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5071
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1134000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1194000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	53417000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	86353000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98859000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98859000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1167863000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1144893000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-105000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	162000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-523692000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-488719000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	644067000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	656337000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	697484000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	742690000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58032000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	167920000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24742000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11913000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	82774000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	179833000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-82774000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-179833000	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	147000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	9150000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3299000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	38651000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-34973000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-267000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	86000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-267000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	86000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35240000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-176364000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.61
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.61
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97913660	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97913660	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20492101	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20492101	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	656337000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20163000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2807000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-34973000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-267000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	644067000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743552	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102862000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	128735000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7139000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	86000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743552	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-143352000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	20163000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7139000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	7000000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2024Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	133057000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5362000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	177000	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	147000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	46000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	16000	usd
CY2024Q1	slrn	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-205000	usd
CY2023Q1	slrn	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-825000	usd
CY2024Q1	slrn	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	-2503000	usd
CY2023Q1	slrn	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	-2196000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-31926000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2990000	usd
CY2024Q1	slrn	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	2093000	usd
CY2023Q1	slrn	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	3565000	usd
CY2024Q1	slrn	Increase Decrease In Accrued Compensation And Other Current Liabilities IncreaseDecreaseInAccruedCompensationAndOtherCurrentLiabilities	-2651000	usd
CY2023Q1	slrn	Increase Decrease In Accrued Compensation And Other Current Liabilities IncreaseDecreaseInAccruedCompensationAndOtherCurrentLiabilities	-1778000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-60000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2024Q1	slrn	Increase Decrease In Severance Liability IncreaseDecreaseInSeveranceLiability	-392000	usd
CY2023Q1	slrn	Increase Decrease In Severance Liability IncreaseDecreaseInSeveranceLiability	3435000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57299000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25329000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	7000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
CY2024Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2023Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	10007000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	198007000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	289567000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	47773000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2391000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	238000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	100896000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47542000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2807000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	129000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2807000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-129000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46404000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22084000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218097000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267110000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264501000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	289194000	usd
CY2024Q1	slrn	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	usd
CY2023Q1	slrn	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	2180000	usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	128735000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1348000	usd
CY2024Q1	slrn	Temporary Equity Convertible Conversion Ratio TemporaryEquityConvertibleConversionRatio	1
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176500000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35000000	usd
CY2024Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	37000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176500000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-523700000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25300000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	678500000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of its derivative tranche liability, the fair value of its common stock, stock-based compensation expense, accruals for research and development expenses, valuation of deferred tax assets, and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span></div>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, and short-term marketable securities are financial instruments that potentially subject the Company to concentrations of credit risk. As of March 31, 2024 and December 31, 2023, cash consists of cash deposited </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with one financial institution, and account balances exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of this institution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investments in money market funds, U.S. Treasury obligations, corporate debt obligations, and federal agency obligations, which can be subject to certain credit risks. The Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments.</span></div>
CY2024Q1	slrn	Concentration Risk Credit Risk Number Of Financial Institutions With Cash Deposits ConcentrationRiskCreditRiskNumberOfFinancialInstitutionsWithCashDeposits	1	institution
CY2022Q4	slrn	Asset Acquisition Number Of Subsidiaries Formed AssetAcquisitionNumberOfSubsidiariesFormed	2	subsidiary
CY2024Q1	slrn	Asset Acquisition Separately Recognized Transactions Severance Payable Current AssetAcquisitionSeparatelyRecognizedTransactionsSeverancePayableCurrent	200000	usd
CY2023Q4	slrn	Asset Acquisition Separately Recognized Transactions Severance Payable Current AssetAcquisitionSeparatelyRecognizedTransactionsSeverancePayableCurrent	300000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	655298000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	711588000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	655298000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	711588000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	655402000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	125000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	655298000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	711426000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	204000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	42000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	711588000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	1200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	800000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2024Q1	slrn	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	7247000	usd
CY2023Q4	slrn	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	8184000	usd
CY2024Q1	slrn	Valued Added Tax Receivable Current ValuedAddedTaxReceivableCurrent	4166000	usd
CY2023Q4	slrn	Valued Added Tax Receivable Current ValuedAddedTaxReceivableCurrent	3985000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1423000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1712000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	1189000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	764000	usd
CY2024Q1	slrn	Prepaid Other Services Current PrepaidOtherServicesCurrent	1418000	usd
CY2023Q4	slrn	Prepaid Other Services Current PrepaidOtherServicesCurrent	667000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15443000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15312000	usd
CY2024Q1	slrn	Prepaid Research And Development Expense Noncurrent PrepaidResearchAndDevelopmentExpenseNoncurrent	141000	usd
CY2023Q4	slrn	Prepaid Research And Development Expense Noncurrent PrepaidResearchAndDevelopmentExpenseNoncurrent	2644000	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	34000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	34000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	175000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2678000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2349000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2294000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	115000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2179000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2179000	usd
CY2024Q1	slrn	Accrued Clinical Manufacturing Expenses Current AccruedClinicalManufacturingExpensesCurrent	26969000	usd
CY2023Q4	slrn	Accrued Clinical Manufacturing Expenses Current AccruedClinicalManufacturingExpensesCurrent	22232000	usd
CY2024Q1	slrn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	10560000	usd
CY2023Q4	slrn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13204000	usd
CY2024Q1	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	37529000	usd
CY2023Q4	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	35436000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2643000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5417000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1020000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1099000	usd
CY2024Q1	slrn	Accrued Liabilities And Current Liabilities Other AccruedLiabilitiesAndCurrentLiabilitiesOther	519000	usd
CY2023Q4	slrn	Accrued Liabilities And Current Liabilities Other AccruedLiabilitiesAndCurrentLiabilitiesOther	317000	usd
CY2024Q1	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	4182000	usd
CY2023Q4	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	6833000	usd
CY2024Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	117700000	usd
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	142300000	usd
CY2023Q1	slrn	Lessee Operating Lease Square Feet Leased LesseeOperatingLeaseSquareFeetLeased	10012	sqft
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P65M
CY2023Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2023Q1	slrn	Lessee Operating Lease Monthly Payments LesseeOperatingLeaseMonthlyPayments	30500	usd
CY2023Q1	slrn	Lessee Operating Lease Annual Rent Increase Percent LesseeOperatingLeaseAnnualRentIncreasePercent	0.030
CY2023Q1	slrn	Lessee Operating Lease Rent Abatement Term LesseeOperatingLeaseRentAbatementTerm	P6M
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	34000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1300000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1300000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	283000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	386000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	398000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	409000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	280000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1756000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	392000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1364000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	230000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1134000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P53M
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2024Q1	us-gaap	Variable Lease Payment VariableLeasePayment	100000	usd
CY2023Q2	slrn	Conversion Of Stock Ratio ConversionOfStockRatio	1
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24980221	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20101379	shares
CY2023Q2	slrn	Conversion Of Stock Ratio ConversionOfStockRatio	1
CY2020Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2839749	shares
CY2020Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.00002
CY2023Q2	slrn	Share Based Compensation Arrangement By Share Based Payment Award And Cash Based Compensation Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardAndCashBasedCompensationMaximum	750000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9220
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0395
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0395
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0339
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0412
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9630623	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.4619
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12007000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3779070	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.6815
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	153916	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.7305
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	360	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.8766
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	339902	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.6418
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12915515	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.7622
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7696000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1925317	shares
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.9361
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4034000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12915515	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.7622
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7696000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2000000.0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.3756
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8737
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8737
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9136
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20163000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7139000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20163000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7139000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-34973000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	98090167	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	21023566	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	176507	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	531465	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97913660	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97913660	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20492101	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20492101	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.61
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.61
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17300334	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	49128447	shares
CY2024Q1	us-gaap	Other Nonrecurring Income OtherNonrecurringIncome	30000000.0	usd
CY2024Q1	slrn	Research And Development Expense Vendor Service Credit ResearchAndDevelopmentExpenseVendorServiceCredit	5000000.0	usd
CY2024Q1	us-gaap	Other Nonrecurring Income OtherNonrecurringIncome	30000000.0	usd
CY2024Q1	slrn	Research And Development Expense Vendor Service Credit ResearchAndDevelopmentExpenseVendorServiceCredit	5000000.0	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	7000000.0	usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	157500000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
slrn-20240331_cal.xml	Edgar Link	unprocessable
0001962918-24-000052-index-headers.html	Edgar Link	pending
0001962918-24-000052-index.html	Edgar Link	pending
0001962918-24-000052.txt	Edgar Link	pending
0001962918-24-000052-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slrn-20240331.htm	Edgar Link	pending
slrn-20240331.xsd	Edgar Link	pending
slrn-20240331x10qexx311.htm	Edgar Link	pending
slrn-20240331x10qexx312.htm	Edgar Link	pending
slrn-20240331x10qexx321.htm	Edgar Link	pending
slrn-20240331_def.xml	Edgar Link	unprocessable
slrn-20240331_lab.xml	Edgar Link	unprocessable
slrn-20240331_pre.xml	Edgar Link	unprocessable
slrn-20240331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRN
ACELYRIN, Inc. Stock $slrn

2024 Q2 Form 10-Q Financial Statement

#000196291824000052 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRN ACELYRIN, Inc. Stock $slrn

2024 Q2 Form 10-Q Financial Statement

#000196291824000052 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRN
ACELYRIN, Inc. Stock $slrn